COMMUNIQUÉS West-GlobeNewswire

New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA’s Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo
18/05/2026
Multicenter prospective RCT published in JAAD confirms superiority of XTRAC® Excimer Laser plus oral JAK inhibitors over tacrolimus combination therapy in children aged 2–18 years with progressive vitiligo, fueling [...]
Alpha Tau to Participate in May Investor Conferences
18/05/2026
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced [...]
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
18/05/2026
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders [...]
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
18/05/2026
Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal. KNOXVILLE, Tenn., May 18, 2026 [...]
SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting
18/05/2026
KING OF PRUSSIA, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company developing rationally designed molecular glue degraders, today announced that it will [...]
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
18/05/2026
Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing Presented new analyses at AAN 2026 highlighting [...]
BrainsWay Announces Minority-Stake Investment in Hopemark Health
18/05/2026
Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access to transformative [...]
Zenflow Presents the BREEZE™ Pivotal Clinical Trial at the American Urological Association Annual Meeting
18/05/2026
Data Supported the FDA Approval of the Zenflow Spring® Implant and Delivery System for BPH Additional presented data highlights patient satisfaction & long-term safety SOUTH SAN FRANCISCO, Calif., May 18, 2026 ( [...]
Glass House Brands Announces the Filing of Prospectus Supplement for Previously Announced At-The-Market Distribution Program
18/05/2026
LONG BEACH, Calif. and TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“ Glass House ” or the “ Company “) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF) announced today that, [...]
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
18/05/2026
Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study initiation on [...]
Nature Human Behaviour study finds SilverCloud® by Amwell® reduced prevalence of mental disorders over two years at scale
18/05/2026
BOSTON, May 18, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today highlighted results from an independently led, [...]
Kraig Biocraft Laboratories Announces Breakthrough Creation of Immortalized Silkworm Silk Gland Cell Line with Broad Biotechnology Applications
18/05/2026
ANN ARBOR, Mich., May 18, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a biotechnology [...]
Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development
18/05/2026
Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a new generation of [...]
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
18/05/2026
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron, consisting of [...]
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
18/05/2026
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18, 2026 [...]
Juniper Biosciences Appoints Renowned Radiopharmaceutical Expert Jason S. Lewis, Ph.D. as Chair of Newly Formed Scientific Advisory Board
18/05/2026
BRIDGEWATER, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences, a cutting-edge radiopharmaceutical drug development company, today announced the launch of its Scientific Advisory Board (SAB) and the appointment [...]
GMR Solutions Inc. Announces Ratings Upgrade and Debt Reduction
18/05/2026
Post-IPO rating improvement from S&P Global Ratings and Moody’s Ratings LEWISVILLE, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- GMR Solutions Inc. (NYSE: GMRS) and its wholly owned subsidiary Global Medical Response, [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
18/05/2026
Key highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026, with favorable [...]
Vincentage Pharma Reports Positive Top-Line Results from Pivotal Phase 3 Trial of VCT220 in Obese or Overweight Chinese Adults
18/05/2026
CHENGDU, China, May 18, 2026 (GLOBE NEWSWIRE) -- Vincentage Pharma Co., Ltd. (the “Company”) today announced positive top-line results from the Company’s pivotal Phase 3 trial evaluating its internally discovered, [...]

Pages